Solvent-Free Abraxane(R) Combined With Targeted Therapy Bevacizumab Evaluated As Firs
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with bevacizumab for the first-line treatment of metastatic breast cancer.
More... |
All times are GMT -7. The time now is 06:16 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021